Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients

Multiple Sclerosis Journal

Volumn 20, Issue 14, 2014, Pages 1851-1859

  Munoz Culla M ^a,b   Irizar, H ^a,b   Castillo Trivino T ^a,b,c   Saenz Cuesta M ^a,b   Sepulveda L ^a   Lopetegi, I ^a   De Munain, A López ^c,d,e   Olascoaga, J ^a,b,c   Baranzini, S E ^f   Otaegui, D ^a,b  

^a BIODONOSTIA HEALTH RESEARCH INSTITUTE   (Spain)

^b Spanish Network on Multiple Sclerosis ^*  (Spain)

^c HOSPITAL DONOSTIA   (Spain)

^d UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^e CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adverse effects; biomarker; microRNA; miRNA expression; multiple sclerosis; natalizumab; progressive multifocal leukoencephaly; risk factors

Indexed keywords

MICRORNA; MICRORNA 125A 5P; MICRORNA 320; MICRORNA 320B; MICRORNA 629; MICRORNA 642; MICRORNA LET 7C; NATALIZUMAB; UNCLASSIFIED DRUG; MIRN125 MICRORNA, HUMAN; MIRN320 MICRORNA, HUMAN; MIRN629 MICRORNA, HUMAN; MIRN642 MICRORNA, HUMAN; MIRNLET7 MICRORNA, HUMAN; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; LONGITUDINAL STUDY; MALE; MULTIPLE SCLEROSIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; THERAPY EFFECT; BLOOD; CASE CONTROL STUDY; CHEMICALLY INDUCED; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; BLOOD SAMPLING; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE MARKER; DRUG EFFECT; PREDICTION; RISK ASSESSMENT; TIME TO TREATMENT; TREATMENT DURATION;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION PROFILING; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MALE; MICRORNAS; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NATALIZUMAB;

EID: 84918771037     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458514534513     Document Type: Article

References (21)

1. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New Engl J Med. 2006 ; 354: 899-910
2. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. New Engl J Med. 2006 ; 354: 911-923
3. Warnke C, Menge T, Hartung HP, et al. Natalizumab and progressive multifocal leukoencephalopathy: What are the causal factors and can it be avoided?. Arch Neurol. 2010 ; 67: 923-930
4. Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. New Engl J Med. 2012 ; 366: 1870-1880
5. Lindberg RL, Achtnichts L, Hoffmann F, et al. Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. J Neuroimmunol. 2008 ; 194: 153-164
6. Brodersen P, Voinnet O. Revisiting the principles of microRNA target recognition and mode of action. Nat Rev Molec Cell Biol. 2009 ; 10: 141-148
7. Mayr M, Zampetaki A, Willeit P, et al. MicroRNAs within the continuum of postgenomics biomarker discovery. Arterioscler Thromb Vasc Biol. 2013 ; 33: 206-214
8. Wang LL, Huang Y, Wang G, et al. The potential role of microRNA-146 in Alzheimer's disease: Biomarker or therapeutic target?. Med Hypoth. 2012 ; 78: 398-401
9. Sievers C, Meira M, Hoffmann F, et al. Altered microRNA expression in B lymphocytes in multiple sclerosis: Towards a better understanding of treatment effects. Clin Immunol. 2012 ; 144: 70-79
10. Shirdel EA, Xie W, Mak TW, Jurisica I. NAViGaTing the micronome-using multiple microRNA prediction databases to identify signalling pathway-associated microRNAs. PloS one. 2011 ; 6: e17429
11. Benita Y, Cao Z, Giallourakis C, et al. Gene enrichment profiles reveal T-cell development, differentiation, and lineage-specific transcription factors including ZBTB25 as a novel NF-AT repressor. Blood. 2010 ; 115: 5376-5384
12. Bindea G, Mlecnik B, Hackl H, et al. ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics. 2009 ; 25: 1091-1093
13. Keller A, Leidinger P, Lange J, et al. Multiple sclerosis: MicroRNA expression profiles accurately differentiate patients with relapsing-remitting disease from healthy controls. PloS One. 2009 ; 4: e7440
14. Junker A, Krumbholz M, Eisele S, et al. MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain. 2009 ; 132: 3342-3352
15. Reijerkerk A, Lopez-Ramirez MA, Van Het Hof B, et al. MicroRNAs regulate human brain endothelial cell-barrier function in inflammation: Implications for multiple sclerosis. J Neurosci. 2013 ; 33: 6857-6863
16. Koudriavtseva T, Sbardella E, Trento E, et al. Long term follow up of peripheral lymphocyte subsets in a cohort of multiple sclerosis patients treated with natalizumab. Clin Exp Immunol. 2014 2014 ; 176: 320-6
17. Krumbholz M, Meinl I, Kumpfel T, et al. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology. 2008 ; 71: 1350-1354
18. Putzki N, Baranwal MK, Tettenborn B, et al. Effects of natalizumab on circulating B cells, T regulatory cells and natural killer cells. Eur Neurol. 2010 ; 63: 311-317
19. Zanotti C, Chiarini M, Serana F, et al. Peripheral accumulation of newly produced T and B lymphocytes in natalizumab-treated multiple sclerosis patients. Clin Immunol. 2012 ; 145: 19-26
20. Wei YF, Cui GY, Ye P, et al. MicroRNAs may solve the mystery of chronic hepatitis B virus infection. World J Gastroenterol. 2013 ; 19: 4867-4876
21. Schwab N, Schneider-Hohendorf T, Posevitz V, et al. L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology. 2013 ; 81: 865-871